Opaleye Management Inc., Opaleye, L.P., and James Silverman filed an amended Schedule 13G with the SEC on November 6, 2026, disclosing their beneficial ownership of common stock in Gossamer Bio, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Opaleye Management Inc. and James Silverman each report beneficial ownership of 426,989 shares, representing 6.98% of Gossamer Bio's common stock.
  • Fund direct holdings: Opaleye, L.P. directly holds 415,000 shares, equating to 6.79% of the class, according to the filing.
  • Separately managed account: An additional 11,989 shares are held in a separately managed account advised by Opaleye Management Inc., bringing the adviser's total to 426,989 shares.
  • Shared voting and dispositive power: All 426,989 shares are held with shared voting and shared dispositive power; sole voting and sole dispositive power are each reported as zero.
  • Share count basis: The percent-of-class figures are based on 6,116,391 common shares issued and outstanding as of September 14, 2026, as reported in Gossamer Bio's definitive proxy statement filed with the SEC on September 16, 2026, which the filing notes "reflects the impact of the Reverse Stock Split."
  • Triggering event date: The date of the event requiring this filing is stated as September 30, 2026.

Opaleye Group Ownership Structure in Gossamer Bio After Reverse Stock Split

According to the amended Schedule 13G, the three reporting persons are Opaleye Management Inc. (the "Adviser"), a Massachusetts-based investment adviser; Opaleye, L.P. (the "Fund"), a Delaware limited partnership; and James Silverman, described as the controlling person of the Adviser. The filing states that the Fund directly holds 415,000 shares of Gossamer Bio common stock, par value $0.0001 per share (CUSIP 38341P201), while 11,989 additional shares are held in a separately managed account also advised by the Adviser. Combined, the Adviser and Mr. Silverman are each reported as beneficially owning 426,989 shares in aggregate.

The filing discloses that the percentage of class calculations rely on the 6,116,391 common shares outstanding as of September 14, 2026, a figure drawn from the issuer's definitive proxy statement filed September 16, 2026. The filing notes this share count "reflects the impact of the Reverse Stock Split." Opaleye, L.P.'s 415,000 shares represent 6.79% of the class, while the broader 426,989-share position held by the Adviser and Mr. Silverman represents 6.98%. The filing states that only Opaleye, L.P.'s interest exceeds 5% of the class with respect to the right to receive dividends and sale proceeds.

The reporting persons are organized at One Boston Place, 26th Floor, Boston, MA 02108. The filing certifies, per the standard Schedule 13G language, that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." This is Amendment No. 1 to a prior Schedule 13G. The filing was signed by James Silverman in his capacities as President of Opaleye Management Inc., Managing Member of Opaleye GP LLC (general partner of Opaleye, L.P.), and individually, all dated November 6, 2026.

What Was Disclosed

Opaleye Management Inc., Opaleye, L.P., and James Silverman filed an amended Schedule 13G disclosing aggregate beneficial ownership of 426,989 shares, or 6.98%, of Gossamer Bio, Inc. common stock as of September 30, 2026, based on a post-reverse-split share count of 6,116,391.